+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Benign Prostatic Hyperplasia Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025

  • ID: 4857384
  • Report
  • October 2019
  • Region: Global
  • 100 pages
  • Infinium Global Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan plc
  • Astellas Pharma, Inc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • MORE
The report on the global benign prostatic hyperplasia treatment market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global benign prostatic hyperplasia treatment market to grow with a CAGR of 8.3% over the forecast period from 2019-2025. The study on benign prostatic hyperplasia treatment market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on benign prostatic hyperplasia treatment market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global benign prostatic hyperplasia treatment market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global benign prostatic hyperplasia treatment market over the period of 2017 to 2025. Further, the Growth Matrix given in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings:

1. Drivers
  • The growing occurrence of benign prostatic hyperplasia coupled with the growing risk factors
  • The increase in the male geriatric population
2. Restraints
  • The high cost of benign prostatic hyperplasia treatment
3. Opportunities
  • The growing preference for in-office based minimally invasive surgical techniques
Research Methodology

A. Primary Research

Primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include:

1. Key Opinion Leaders associated with the publisher
2. Internal and External subject matter experts
3. Professionals and participants from the industry

Primary research respondents typically include:

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B. Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include:

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered

The global benign prostatic hyperplasia treatment market is segmented on the basis of therapeutic class, therapy, and end-user.

The Global Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class
  • Alpha-blocker
  • Phosphodiesterase-5 Inhibitor
  • 5-alpha Reductase Inhibitor
  • Other Therapeutic Class
The Global Benign Prostatic Hyperplasia Treatment Market by Therapy
  • Mono Drug Therapy
  • Combination Drug Therapy
The Global Benign Prostatic Hyperplasia Treatment Market by End-User
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Other End Users
Company Profiles

The companies covered in the report include
  • Allergan plc
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Astellas Pharma, Inc.
  • Abbott Laboratories
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Sanofi
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
What does this report deliver?

1. Comprehensive analysis of the global as well as regional markets of the benign prostatic hyperplasia treatment market.
2. Complete coverage of all the segments in the benign prostatic hyperplasia treatment market to analyze the trends, developments in the global market and forecast of market size up to 2025.
3. Comprehensive analysis of the companies operating in the global benign prostatic hyperplasia treatment market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. The Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan plc
  • Astellas Pharma, Inc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • MORE
1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary
2.1. Benign Prostatic Hyperplasia Treatment Market Highlights
2.2. Benign Prostatic Hyperplasia Treatment Market Projection
2.3. Benign Prostatic Hyperplasia Treatment Market Regional Highlights

3. Global Benign Prostatic Hyperplasia Treatment Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Therapeutic Class
3.4.2. Growth Matrix Analysis by Therapy
3.4.3. Growth Matrix Analysis by End-User
3.4.4. Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Benign Prostatic Hyperplasia Treatment Market

4. Benign Prostatic Hyperplasia Treatment Market Macro Indicator Analysis

5. Global Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class
5.1. Alpha-blocker
5.2. Phosphodiesterase-5 Inhibitor
5.3. 5-alpha Reductase Inhibitor
5.4. Other Therapeutic Class

6. Global Benign Prostatic Hyperplasia Treatment Market by Therapy
6.1. Mono Drug Therapy
6.2. Combination Drug Therapy

7. Global Benign Prostatic Hyperplasia Treatment Market by End-User
7.1. Hospitals
7.2. Specialty Clinics
7.3. Ambulatory Surgical Centers
7.4. Other End Users

8. Global Benign Prostatic Hyperplasia Treatment Market by Region 2019-2025
8.1. North America
8.1.1. North America Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class
8.1.2. North America Benign Prostatic Hyperplasia Treatment Market by Therapy
8.1.3. North America Benign Prostatic Hyperplasia Treatment Market by End-User
8.1.4. North America Benign Prostatic Hyperplasia Treatment Market by Country
8.2. Europe
8.2.1. Europe Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class
8.2.2. Europe Benign Prostatic Hyperplasia Treatment Market by Therapy
8.2.3. Europe Benign Prostatic Hyperplasia Treatment Market by End-User
8.2.4. Europe Benign Prostatic Hyperplasia Treatment Market by Country
8.3. Asia-Pacific
8.3.1. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class
8.3.2. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market by Therapy
8.3.3. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market by End-User
8.3.4. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market by Country
8.4. RoW
8.4.1. RoW Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class
8.4.2. RoW Benign Prostatic Hyperplasia Treatment Market by Therapy
8.4.3. RoW Benign Prostatic Hyperplasia Treatment Market by End-User
8.4.4. RoW Benign Prostatic Hyperplasia Treatment Market by Sub-region

9. Company Profiles and Competitive Landscape
9.1. Competitive Landscape in the Global Benign Prostatic Hyperplasia Treatment Market
9.2. Companies Profiled
9.2.1. Allergan plc
9.2.2. Eli Lilly and Company
9.2.3. Pfizer, Inc.
9.2.4. Astellas Pharma, Inc.
9.2.5. Abbott Laboratories
9.2.6. Boehringer Ingelheim GmbH
9.2.7. GlaxoSmithKline plc
9.2.8. Sanofi
9.2.9. Merck & Co., Inc.
9.2.10. Teva Pharmaceutical Industries Ltd.

10. Appendix
10.1. Primary Research Findings and Questionnaire
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allergan plc
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Astellas Pharma, Inc.
  • Abbott Laboratories
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Sanofi
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll